583 related articles for article (PubMed ID: 34844845)
1. Understanding and targeting prostate cancer cell heterogeneity and plasticity.
Tang DG
Semin Cancer Biol; 2022 Jul; 82():68-93. PubMed ID: 34844845
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.
Deng Q; Tang DG
Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness.
Liu X; Li WJ; Puzanov I; Goodrich DW; Chatta G; Tang DG
Essays Biochem; 2022 Sep; 66(4):291-303. PubMed ID: 35866337
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
Jamroze A; Chatta G; Tang DG
Cancer Lett; 2021 Oct; 518():1-9. PubMed ID: 34118355
[TBL] [Abstract][Full Text] [Related]
5. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.
Bishop JL; Davies A; Ketola K; Zoubeidi A
Endocr Relat Cancer; 2015 Jun; 22(3):R165-82. PubMed ID: 25934687
[TBL] [Abstract][Full Text] [Related]
6. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
7. Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.
Liu X; Chen X; Rycaj K; Chao HP; Deng Q; Jeter C; Liu C; Honorio S; Li H; Davis T; Suraneni M; Laffin B; Qin J; Li Q; Yang T; Whitney P; Shen J; Huang J; Tang DG
Oncotarget; 2015 Sep; 6(27):23959-86. PubMed ID: 26246472
[TBL] [Abstract][Full Text] [Related]
8. Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis.
Tian J; Lee SO; Liang L; Luo J; Huang CK; Li L; Niu Y; Chang C
J Biol Chem; 2012 Nov; 287(47):39954-66. PubMed ID: 23012352
[TBL] [Abstract][Full Text] [Related]
9. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
[TBL] [Abstract][Full Text] [Related]
10. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
Brady NJ; Bagadion AM; Singh R; Conteduca V; Van Emmenis L; Arceci E; Pakula H; Carelli R; Khani F; Bakht M; Sigouros M; Bareja R; Sboner A; Elemento O; Tagawa S; Nanus DM; Loda M; Beltran H; Robinson B; Rickman DS
Nat Commun; 2021 Jun; 12(1):3372. PubMed ID: 34099734
[TBL] [Abstract][Full Text] [Related]
11. New insights into prostate cancer stem cells.
Chen X; Rycaj K; Liu X; Tang DG
Cell Cycle; 2013 Feb; 12(4):579-86. PubMed ID: 23370446
[TBL] [Abstract][Full Text] [Related]
12. Molecular Origin, Expression Regulation, and Biological Function of Androgen Receptor Splicing Variant 7 in Prostate Cancer.
Chen Y; Lan T
Urol Int; 2021; 105(5-6):337-353. PubMed ID: 32957106
[TBL] [Abstract][Full Text] [Related]
13. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.
Lee SO; Ma Z; Yeh CR; Luo J; Lin TH; Lai KP; Yamashita S; Liang L; Tian J; Li L; Jiang Q; Huang CK; Niu Y; Yeh S; Chang C
J Mol Cell Biol; 2013 Feb; 5(1):14-26. PubMed ID: 22831834
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell and mesenchymal cell cooperative actions in metastasis progression and hormone resistance in prostate cancer: Potential role of androgen and gonadotropin‑releasing hormone receptors (Review).
Contreras HR; López-Moncada F; Castellón EA
Int J Oncol; 2020 May; 56(5):1075-1082. PubMed ID: 32319606
[TBL] [Abstract][Full Text] [Related]
15. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
Gu Y; Xue M; Wang Q; Hong X; Wang X; Zhou F; Sun J; Wang G; Peng Y
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948018
[No Abstract] [Full Text] [Related]
16. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
17. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.
Lin CY; Jan YJ; Kuo LK; Wang BJ; Huo C; Jiang SS; Chen SC; Kuo YY; Chang CR; Chuu CP
Cancer Sci; 2018 Nov; 109(11):3564-3574. PubMed ID: 30142696
[TBL] [Abstract][Full Text] [Related]
18. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
Sabnis NG; Miller A; Titus MA; Huss WJ
Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
[TBL] [Abstract][Full Text] [Related]
19. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells.
Heemers HV; Schmidt LJ; Kidd E; Raclaw KA; Regan KM; Tindall DJ
Prostate; 2010 Jun; 70(9):959-70. PubMed ID: 20166126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]